ACCURAY INC ARAY
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
6/9
Piotroski F — financial health
-1.53
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $458.5M | -$1.6M | $147.0M | -$1.4M | $81.2M |
| 2024 | $446.6M | -$15.5M | $142.9M | -$15.5M | $45.1M |
| 2023 | $447.6M | -$9.3M | $154.0M | $2.9M | $53.7M |
| 2022 | $429.9M | -$5.3M | $160.0M | -$7.1M | $53.2M |
| 2021 | $396.3M | -$6.3M | $159.5M | $36.2M | $68.8M |
| 2020 | $382.9M | $3.8M | $149.7M | -$5.0M | $63.6M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.53 (distress)
- Working capital / assets 0.266
- Retained earnings / assets -1.104
- EBIT / assets 0.017
- Equity / liabilities 0.209
Source: SEC EDGAR filings · CIK 0001138723 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.